Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC – Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn:
”Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for the treatment of non-small cell lung cancer (IMMONC0008) – NCT06322108.
IMMONC in collaboration with Agenus, has launched a new trial, which will assess the safety and efficacy of the anti-CTLA-4 agent (Botensilimab in combination with anti-PD-1 antibody Balstilimab in the frontline treatment of metastatic non-small cell lung cancer (NSCLC).
The study will enroll participants with a histologically confirmed diagnosis of metastatic NSCLC and without targetable EGFR mutation or ALK rearrangement, while excluding those with untreated brain metastases or oligometastatic disease lacking targetable lesions.
The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods.
The Principal Investigator of the trial is Dr. Samvel Bardakhchyan, the study team includes Professor Gevorg Tamamyan, Dr. Davit Zohrabyan, Dr. Liana Safaryan and Dr. Amalya Sargsyan.”
View attached video.
Source: Immune Oncology Research Institute/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023